

**All-round miss; guidance also sees sharp cut**

Information Technology ▶ Result Update ▶ July 26, 2024

**TARGET PRICE (Rs): 2,300**

**Cyient logged a weak set of results in Q1, widely missing consensus/our estimate. DET revenue fell 5.4% QoQ (-5% cc) – much lower than our estimate of 1.6% QoQ decline. DET EBITM also, fell by 250bps QoQ to 13.5%, missing our estimate. The mgmt attributed this weakness to longer than anticipated delays, right shift in project execution in Connectivity, and persisting challenges in Rail. Also, guidance was sharply cut to flattish YoY growth in FY25 (implying 3.2% CQGR over Q2-Q4) from high single-digit growth earlier, with H2 expected to be better than H1. We cut FY25E-27E EPS by 5%-13%, factoring-in the Q1 miss, sharp guidance cut, and gradual recovery in DET margin. We cut target multiple to 25x (from 27x), given the sharp guidance cut within only a Quarter raising concerns on growth predictability. A big earnings miss will weigh on the near-term stock performance, but valuations remain fairly undemanding. We retain BUY on Cyient, pulling down our TP to Rs2,300/sh (valuing the DET business at 25x Jun-26E, and the DLM business at 20% discount to the CMP).**

**Cyient: Financial Snapshot (Consolidated)**

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	60,159	71,471	74,038	86,233	1,00,677
EBITDA	10,240	13,027	12,519	15,200	18,024
Adj. PAT	5,766	7,348	7,013	9,122	11,143
Adj. EPS (Rs)	46.6	61.6	63.2	82.2	100.5
EBITDA margin (%)	17.0	18.2	16.9	17.6	17.9
EBITDA growth (%)	24.6	27.2	(3.9)	21.4	18.6
Adj. EPS growth (%)	(1.6)	32.3	2.7	30.1	22.2
RoE (%)	17.5	19.0	15.8	18.8	20.7
RoIC (%)	20.9	21.0	18.9	22.9	25.9
P/E (x)	36.3	28.6	30.0	23.0	18.9
EV/EBITDA (x)	21.0	16.0	16.4	13.4	11.2
P/B (x)	6.0	4.9	4.5	4.1	3.7
FCFF yield (%)	2.3	3.1	3.3	2.6	3.7

Source: Company, Emkay Research

**Result summary**

Cyient DET revenue declined 5.6% QoQ (5% drop in cc terms) to US\$169.6mn, well below our estimate of US\$176.4mn. All verticals posted a QoQ decline in revenue, with Transportation, Connectivity, Sustainability, and New Growth Areas falling 7%, 7.6%, 2.8%, and 1.6% QoQ CC, respectively. Among geographies, Americas saw an uptick of 1.7% QoQ, while EMEA and Asia Pacific sharply declined 14.3% and 5.4%, respectively. Revenue for Top-5 and Top-10 clients declined 3.3% and 2.5% QoQ, respectively. DET adjusted margin fell by 250bps QoQ to 13.5%, considerably lower than our estimate of 15.6%, impacted by sequential revenue dip and continued investments in sales and technology. Order intake was US\$182.7mn in Q1. Cyient also signed 5 large deals with total contract potential of US\$52.4mn in Q1. Total headcount declined 2.4% QoQ to 15,083. **What we liked:** Double-digit growth in the order book (YoY). **What we did not like:** Weak operating performance; sharp cut in FY25 DET guidance.


**Earnings call KTAs**

i) Q1 saw a significant number of operational challenges resulting in operational performance clocking weaker than the management’s expectation. However, it is confident of a robust recovery starting Q2 which is expected to continue through the year, aided by double-digit YoY growth in order backlog, top-10 clients seeing double-digit growth YoY, and strong outlook on core segments. ii) The management expects H2 to be better than H1. iii) Considering near-term growth challenges, the company will come up with revised EBITM guidance for FY25 in Q3, but it is confident of reaching ~16% by Q4. iv) Connectivity declined 7.6% CC QoQ, although Cyient expects strong recovery on the back of robust order intake. v) Sustainability declined 2.8% CC QoQ, and Cyient expects growth to return in coming quarters. vi) New Growth Areas declined 1.6% CC QoQ, with expectations of double-digit growth by FY25-end on the back of highest-ever order book. vii) It closed 5 large deals with total contract potential of US\$52mn (2 each from connectivity and sustainability, and 1 from Aero). viii) Cyient has made significant progress on GenAI and won >15 projects in Q1, covering various elements of product data management, engineering, information management, AI assisted PMO, customer experience, customer support, product support. ix) Wage hike is wef Q2. x) Cyient has set up a subsidiary to focus on the ASIC turnkey design and manufacturing, through a fabless model for analog mixed signal chips.

Target Price – 12M	Jun-25
<b>Change in TP (%)</b>	<b>(11.5)</b>
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	21.4
CMP (25-Jul-24) (Rs)	1,894.2

Stock Data	Ticker
52-week High (Rs)	2,459
52-week Low (Rs)	1,423
Shares outstanding (mn)	110.9
Market-cap (Rs bn)	210
Market-cap (USD mn)	2,510
Net-debt, FY25E (Rs mn)	-5,007
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	1,008.9
ADTV-3M (USD mn)	12.1
Free float (%)	76.0
Nifty-50	24,406
INR/USD	83.7
<b>Shareholding, Jun-24</b>	
Promoters (%)	23.2
FPIs/MFs (%)	29.5/27.1

Price Performance			
(%)	1M	3M	12M
Absolute	1.5	(1.1)	29.2
Rel. to Nifty	(1.4)	(8.5)	4.2



**Dipesh Mehta**  
dipeshkumar.mehta@emkayglobal.com  
+91 22 6612 1253

**Ayush Bansal**  
ayush.bansal@emkayglobal.com  
+91 22 6612 1344

**Pulkit Chawla**  
pulkit.chawla@emkayglobal.com  
+91 22 6642 4258

**Exhibit 1: Quarterly snapshot**

(Rs mn)	Q1FY25	Q4FY24	QoQ chg	Q1FY24	YoY chg
Net sales - DET (US\$ mn)	169.6	179.3	-5.4%	177.1	-4.2%
Net sales (US\$ mn)	200.9	224.0	-10.3%	205.3	-2.1%
Net sales	16,757	18,607	-9.9%	16,865	-0.6%
Operating expenses	14,106	15,254	-7.5%	13,709	2.9%
EBITDA	2,651	3,353	-20.9%	3,156	-16.0%
- Margins	15.8%	18.0%	-220	18.7%	-290
Depreciation	658	671		676	
EBIT	1,993	2,682	-25.7%	2,480	-19.6%
- Margins	11.9%	14.4%	-250	14.7%	-280
Interest cost	257	324		278	
Other income	211	235		102	
Pre-tax profit	1,947	2,593	-24.9%	2,304	-15.5%
Tax provided	471	623		527	
Profit after tax	1,476	1,970	-25.1%	1,777	-16.9%
Net income	1,439	1,893	-24.0%	1,767	-18.6%
Emkay Net profit	1,439	1,893	-24.0%	1,682	-14.4%
EPS (Rs)	13.0	17.1	-24.0%	15.2	-14.7%

Source: Company, Emkay Research

**Exhibit 2: Actuals vs estimates**

(Rs mn)	Actual	Estimates		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Revenues (US\$ mn)	200.9	217.6	211.7	-7.7%	-5.1%	Revenue growth was below expectations.
Sales	16,757	18,148	17,657	-7.7%	-5.1%	
EBIT	1,993	2,527	2,467	-21.1%	-19.2%	EBITM was below expectations.
EBIT margin	11.9%	13.9%	14.0%	-200 bps	-210 bps	
PAT	1,439	1,824	1,795	-21.1%	-19.8%	Reported profit was lower due to operating performance miss.

Source: Company, Bloomberg, Emkay Research

**Exhibit 3: Changes in estimates**

(Rs mn)	FY25E			FY26E			FY27E		
	Old	New	Change	Old	New	Change	Old	New	Change
Revenue (US\$ mn)	927.5	882.8	-4.8%	1056.1	1014.5	-3.9%	1204.6	1170.7	-2.8%
YoY growth	7.5%	2.3%		13.9%	14.9%		14.1%	15.4%	
Revenue	77,776	74,038	-4.8%	89,768	86,233	-3.9%	1,03,595	1,00,677	-2.8%
EBIT	11,232	9,733	-13.3%	13,553	12,362	-8.8%	15,822	15,016	-5.1%
EBIT margin	14.4%	13.1%		15.1%	14.3%		15.3%	14.9%	
Net profit	8,068	7,013	-13.1%	9,942	9,122	-8.2%	11,700	11,143	-4.8%
EPS (Rs)	72.8	63.2	-13.1%	89.7	82.2	-8.3%	105.5	100.5	-4.8%


Source: Company, Emkay Research

**Exhibit 4: SoTP-based valuation**

Particular (Rs bn)	Jun-26E TTM Profit	Methodology	Target multiple (x)	Valuation (Rs bn)	Valuation (Rs/sh)
Cyient - DET	9	P/E	25	219	1,973
	Mkt cap (Rs bn)	20% discount to CMP	% stake		
Cyient - DLM	61	49	66.7%	33	294
<b>Total</b>				<b>251</b>	<b>2,267</b>
O/S no. of shares	111				
<b>Emkay Target price (Rs/sh)</b>	<b>2,300</b>				
CMP (Rs/sh)	1,894				
Upside	21.4%				
<b>Implied P/E valuation (x)</b>	<b>29.3</b>				

Source: Company, Emkay Research

**Exhibit 5: CYL – One-year forward PER**



Source: Company, Emkay Research

## Cyient: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
<b>Revenue</b>	<b>60,159</b>	<b>71,471</b>	<b>74,038</b>	<b>86,233</b>	<b>1,00,677</b>
Revenue growth (%)	32.7	18.8	3.6	16.5	16.7
<b>EBITDA</b>	<b>10,240</b>	<b>13,027</b>	<b>12,519</b>	<b>15,200</b>	<b>18,024</b>
EBITDA growth (%)	24.6	27.2	(3.9)	21.4	18.6
Depreciation & Amortization	2,566	2,666	2,786	2,837	3,008
<b>EBIT</b>	<b>7,674</b>	<b>10,361</b>	<b>9,733</b>	<b>12,362</b>	<b>15,016</b>
EBIT growth (%)	21.9	35.0	(6.1)	27.0	21.5
Other operating income	0	0	0	0	0
Other income	814	661	897	1,026	1,104
Financial expense	999	1,160	994	733	613
<b>PBT</b>	<b>7,489</b>	<b>9,862</b>	<b>9,637</b>	<b>12,655</b>	<b>15,507</b>
Extraordinary items	(622)	(519)	0	0	0
Taxes	1,723	2,314	2,355	3,164	3,877
Minority interest	0	(200)	(270)	(369)	(487)
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>5,144</b>	<b>6,829</b>	<b>7,013</b>	<b>9,122</b>	<b>11,143</b>
PAT growth (%)	(1.5)	32.8	2.7	30.1	22.2
<b>Adjusted PAT</b>	<b>5,766</b>	<b>7,348</b>	<b>7,013</b>	<b>9,122</b>	<b>11,143</b>
<b>Diluted EPS (Rs)</b>	<b>46.6</b>	<b>61.6</b>	<b>63.2</b>	<b>82.2</b>	<b>100.5</b>
Diluted EPS growth (%)	(1.6)	32.3	2.7	30.1	22.2
<b>DPS (Rs)</b>	<b>26.0</b>	<b>30.0</b>	<b>30.5</b>	<b>40.0</b>	<b>48.5</b>
<b>Dividend payout (%)</b>	<b>55.8</b>	<b>48.7</b>	<b>48.2</b>	<b>48.6</b>	<b>48.3</b>
EBITDA margin (%)	17.0	18.2	16.9	17.6	17.9
EBIT margin (%)	12.8	14.5	13.1	14.3	14.9
Effective tax rate (%)	23.0	23.5	24.4	25.0	25.0
<b>NOPLAT (pre-IndAS)</b>	<b>5,908</b>	<b>7,930</b>	<b>7,355</b>	<b>9,272</b>	<b>11,262</b>
Shares outstanding (mn)	110.5	110.9	110.9	110.9	110.9

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	7,489	9,862	9,637	12,655	15,507
Others (non-cash items)	247	(2,770)	(2,098)	(4,152)	(5,722)
Taxes paid	1,288	2,775	2,355	3,164	3,877
Change in NWC	(3,485)	(2,606)	(1,735)	(3,961)	(4,719)
<b>Operating cash flow</b>	<b>5,539</b>	<b>7,261</b>	<b>8,159</b>	<b>7,705</b>	<b>8,942</b>
Capital expenditure	(652)	(782)	(1,222)	(2,162)	(1,216)
Acquisition of business	(660)	661	0	0	0
Interest & dividend income	444	352	897	1,026	1,104
<b>Investing cash flow</b>	<b>(10,327)</b>	<b>(5,327)</b>	<b>(324)</b>	<b>(1,136)</b>	<b>(112)</b>
Equity raised/(repaid)	79	7,041	0	0	0
Debt raised/(repaid)	3,511	(4,458)	(343)	(1,400)	0
Payment of lease liabilities	(1,395)	(1,257)	0	0	0
Interest paid	(658)	(930)	(994)	(733)	(613)
Dividend paid (incl tax)	(2,630)	(3,058)	(3,383)	(4,437)	(5,379)
Others	0	0	0	0	0
<b>Financing cash flow</b>	<b>(1,093)</b>	<b>(2,662)</b>	<b>(4,720)</b>	<b>(6,570)</b>	<b>(5,993)</b>
Net chg in Cash	(5,881)	(728)	3,115	(1)	2,837
OCF	5,539	7,261	8,159	7,705	8,942
Adj. OCF (w/o NWC chg.)	9,024	9,867	9,895	11,667	13,661
FCFF	4,887	6,479	6,938	5,543	7,726
FCFE	4,332	5,671	6,841	5,836	8,217
OCF/EBITDA (%)	54.1	55.7	65.2	50.7	49.6
FCFE/PAT (%)	84.2	83.0	97.6	64.0	73.7
<b>FCFF/NOPLAT (%)</b>	<b>82.7</b>	<b>81.7</b>	<b>94.3</b>	<b>59.8</b>	<b>68.6</b>

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	553	555	555	555	555
Reserves & Surplus	34,114	42,026	45,656	50,341	56,105
<b>Net worth</b>	<b>34,667</b>	<b>42,581</b>	<b>46,210</b>	<b>50,896</b>	<b>56,659</b>
Minority interests	(32)	2,988	2,988	2,988	2,988
Deferred tax liability (net)	348	87	(402)	(402)	(402)
<b>Total debt</b>	<b>13,448</b>	<b>7,880</b>	<b>7,943</b>	<b>6,610</b>	<b>6,689</b>
<b>Total liabilities &amp; equity</b>	<b>48,431</b>	<b>53,536</b>	<b>56,739</b>	<b>60,091</b>	<b>65,934</b>
Net tangible fixed assets	4,481	4,462	4,415	4,403	4,370
Net intangible assets	5,050	4,397	3,669	2,991	2,309
Net ROU assets	2,770	3,271	2,966	3,173	3,384
Capital WIP	27	16	16	16	16
Goodwill	16,363	16,692	16,692	16,692	16,692
Investments [JV/Associates]	4,395	4,855	4,959	5,126	5,324
<b>Cash &amp; equivalents</b>	<b>7,194</b>	<b>9,835</b>	<b>12,950</b>	<b>12,949</b>	<b>15,786</b>
Current assets (ex-cash)	24,719	25,756	27,651	32,825	(15,786)
Current Liab. & Prov.	16,568	15,748	16,578	18,084	21,052
<b>NWC (ex-cash)</b>	<b>8,151</b>	<b>10,008</b>	<b>11,073</b>	<b>14,741</b>	<b>18,052</b>
<b>Total assets</b>	<b>48,431</b>	<b>53,536</b>	<b>56,739</b>	<b>60,091</b>	<b>65,934</b>
Net debt	6,254	(1,955)	(5,007)	(6,340)	(9,098)
Capital employed	48,431	53,536	56,739	60,091	65,934
<b>Invested capital</b>	<b>36,815</b>	<b>38,830</b>	<b>38,814</b>	<b>42,000</b>	<b>44,808</b>
BVPS (Rs)	313.8	384.0	416.6	458.9	510.8
Net Debt/Equity (x)	0.2	0.0	(0.1)	(0.1)	(0.2)
Net Debt/EBITDA (x)	0.6	(0.2)	(0.4)	(0.4)	(0.5)
Interest coverage (x)	0.1	0.1	0.1	0.1	0.0
<b>RoCE (%)</b>	<b>19.7</b>	<b>21.6</b>	<b>19.3</b>	<b>22.9</b>	<b>25.6</b>

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	36.3	28.6	30.0	23.0	18.9
P/CE(x)	25.1	21.0	21.4	17.6	14.8
P/B (x)	6.0	4.9	4.5	4.1	3.7
EV/Sales (x)	3.6	2.9	2.8	2.4	2.0
EV/EBITDA (x)	21.0	16.0	16.4	13.4	11.2
EV/EBIT(x)	28.1	20.1	21.1	16.5	13.4
EV/IC (x)	5.9	5.4	5.3	4.9	4.5
FCFF yield (%)	2.3	3.1	3.3	2.6	3.7
FCFE yield (%)	2.1	2.7	3.3	2.8	3.9
Dividend yield (%)	1.4	1.6	1.6	2.1	2.6
<b>DuPont-RoE split</b>					
Net profit margin (%)	9.6	10.3	9.5	10.6	11.1
Total asset turnover (x)	1.4	1.4	1.3	1.5	1.6
Assets/Equity (x)	1.3	1.3	1.2	1.2	1.2
<b>RoE (%)</b>	<b>17.5</b>	<b>19.0</b>	<b>15.8</b>	<b>18.8</b>	<b>20.7</b>
<b>DuPont-RoIC</b>					
NOPLAT margin (%)	9.8	11.1	9.9	10.8	11.2
IC turnover (x)	2.1	1.9	1.9	2.1	2.3
<b>RoIC (%)</b>	<b>20.9</b>	<b>21.0</b>	<b>18.9</b>	<b>22.9</b>	<b>25.9</b>
<b>Operating metrics</b>					
Core NWC days	49.5	51.1	54.6	62.4	65.4
<b>Total NWC days</b>	<b>49.5</b>	<b>51.1</b>	<b>54.6</b>	<b>62.4</b>	<b>65.4</b>
Fixed asset turnover	3.2	2.8	2.9	3.5	4.2
Opex-to-revenue (%)	71.9	81.8	83.1	82.4	82.1

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/15/2024 11:24 AM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jul-24	1,843	2,600	Buy	Dipeshkumar Mehta
09-Jun-24	1,925	2,600	Buy	Dipeshkumar Mehta
03-Jun-24	1,731	2,600	Buy	Dipeshkumar Mehta
27-May-24	1,808	2,600	Buy	Dipeshkumar Mehta
26-Apr-24	1,886	2,600	Buy	Dipeshkumar Mehta
31-Mar-24	1,996	2,700	Buy	Dipeshkumar Mehta
01-Mar-24	2,036	2,700	Buy	Dipeshkumar Mehta
26-Jan-24	2,020	2,700	Buy	Dipeshkumar Mehta
03-Jan-24	2,285	2,700	Buy	Dipeshkumar Mehta

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 26, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 26, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 26, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com



**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.